Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03750552




Registration number
NCT03750552
Ethics application status
Date submitted
20/11/2018
Date registered
23/11/2018
Date last updated
14/09/2022

Titles & IDs
Public title
Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
Scientific title
A Phase 3, 4-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure
Secondary ID [1] 0 0
2018-003289-15
Secondary ID [2] 0 0
0169
Universal Trial Number (UTN)
Trial acronym
SEQUOIA
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Symptomatic Neurogenic Orthostatic Hypotension 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system
Neurological 0 0 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - ampreloxetine
Treatment: Drugs - Placebo

Experimental: ampreloxetine - Participants randomized to ampreloxetine will receive a single, oral, daily dose of active drug for 4 weeks.

Placebo Comparator: Placebo - Participants randomized to Placebo will receive a single, oral, daily dose of placebo for 4 weeks.


Treatment: Drugs: ampreloxetine
Oral tablet, QD

Treatment: Drugs: Placebo
Oral tablet, QD
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline in Orthostatic Hypotension Symptom Assessment (OHSA) Question #1 Score at Week 4
Timepoint [1] 0 0
Baseline and Week 4
Secondary outcome [1] 0 0
Change From Baseline in Orthostatic Hypotension Symptom Assessment (OHSA) Composite Score at Week 4
Timepoint [1] 0 0
Baseline and Week 4
Secondary outcome [2] 0 0
Change From Baseline in Orthostatic Hypotension Daily Activities Scale (OHDAS) Composite Score at Week 4
Timepoint [2] 0 0
Baseline and Week 4
Secondary outcome [3] 0 0
Number of Participants Who Experienced an Improvement From Baseline in Patient Global Impression of Change (PGI-C) Score at Week 4
Timepoint [3] 0 0
Baseline and Week 4
Secondary outcome [4] 0 0
Number of Participants Who Experienced at Least One Fall
Timepoint [4] 0 0
Up to Week 4

Eligibility
Key inclusion criteria
- Subject is male or female and at least 30 years old.

- Subject must meet the diagnostic criteria of symptomatic nOH, as demonstrated by a
sustained reduction in BP of =20 mm Hg (systolic) or =10 mm Hg (diastolic) within 3
minutes of being tilted-up to =60o from a supine position as determined by a
tilt-table test.

- Subject must score at least a 4 on the Orthostatic Hypotension Symptom Assessment
Question #1 at randomization visit.

- For subjects with PD only: Subject has a diagnosis of PD according to the United
Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Criteria (1992).

- For subjects with MSA only: Subject has a diagnosis of possible or probable MSA of the
Parkinsonian subtype (MSA-P) or cerebellar subtype (MSA-C) according to The Gilman
Criteria (2008).

- For subjects with PAF only: Subject has documented impaired autonomic reflexes,
including the Valsalva maneuver performed within 24 months from the date of
randomization.

- Subject has plasma NE levels >100 pg/mL after being in seated position for 30 minutes.
Minimum age
30 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Subject has a known systemic illness known to produce autonomic neuropathy, including
but not limited to amyloidosis, and autoimmune neuropathies.

- Subject has a known intolerance to other NRIs or SNRIs.

- Subject currently uses concomitant antihypertensive medication for the treatment of
essential hypertension unrelated to autonomic dysfunction.

- Subject has used strong CYP1A2 inhibitors or inducers within 7 days or 5 half-lives,
whichever is longer, prior to randomization or requires concomitant use until the
follow-up visit.

- Subject has changed dose, frequency, or type of prescribed medication for orthostatic
hypotension within 7 days prior to V1.

- Midodrine and droxidopa (if applicable) must be tapered off at least 7 days prior
to V1.

- Subject has a known or suspected alcohol or substance abuse within the past 12 months
(DSM-IV-TR® definition of alcohol or substance abuse).

- Subject has a clinically unstable coronary artery disease, or major cardiovascular or
neurological event in the past 6 months.

- Subject has used any monoamine oxidase inhibitor (MAO-I) within 14 days prior to
randomization.

- Subject has a history of untreated closed angle glaucoma, or treated closed angle
glaucoma that, in the opinion of an ophthalmologist, might result in an increased risk
to the subject.

- Subject has any significant uncontrolled cardiac arrhythmia.

- Subject has a Montreal Cognitive Assessment (MoCA) =23.

- Subject had a myocardial infarction in the past 6 months or has current unstable
angina.

- Subject has known congestive heart failure (New York Heart Association [NYHA] Class 3
or 4).

- Subject has a clinically significant abnormal laboratory findings (e.g., alanine
aminotransferase [ALT] or aspartate aminotransferase [AST] >3.0 x upper limit of
normal [ULN]; blood bilirubin [total] >1.5 x ULN; estimated glomerular filtration rate
(eGFR) <30 mL/min/1.73m2, or any abnormal laboratory value that could interfere with
safety of the subject).

- Subject has demonstrated a history of lifetime suicidal ideation and/or suicidal
behavior, as outlined by the C-SSRS (Columbia Suicide Severity Rating Scale)
(Baseline/Screening Version) subject should be assessed by the rater for risk of
suicide and the subject's appropriateness for inclusion in the study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
24/01/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
21/07/2021
Sample size
Target
Accrual to date
Final
195
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Concord Hospital - Concord
Recruitment hospital [2] 0 0
Royal Brisbane and Women's Hospital - Herston
Recruitment hospital [3] 0 0
Monash Health - Clinical Trials Centre - Clayton
Recruitment hospital [4] 0 0
The Royal Melbourne Hospital - Parkville
Recruitment hospital [5] 0 0
Perron Institute for Neurological and Translational Science, QEII Medical Centre - Nedlands
Recruitment postcode(s) [1] 0 0
2139 - Concord
Recruitment postcode(s) [2] 0 0
4029 - Herston
Recruitment postcode(s) [3] 0 0
3168 - Clayton
Recruitment postcode(s) [4] 0 0
3050 - Parkville
Recruitment postcode(s) [5] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
District of Columbia
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Kansas
Country [8] 0 0
United States of America
State/province [8] 0 0
Minnesota
Country [9] 0 0
United States of America
State/province [9] 0 0
New Jersey
Country [10] 0 0
United States of America
State/province [10] 0 0
New York
Country [11] 0 0
United States of America
State/province [11] 0 0
Ohio
Country [12] 0 0
United States of America
State/province [12] 0 0
Oregon
Country [13] 0 0
United States of America
State/province [13] 0 0
Tennessee
Country [14] 0 0
United States of America
State/province [14] 0 0
Texas
Country [15] 0 0
United States of America
State/province [15] 0 0
Virginia
Country [16] 0 0
United States of America
State/province [16] 0 0
Washington
Country [17] 0 0
Austria
State/province [17] 0 0
Innsbruck
Country [18] 0 0
Austria
State/province [18] 0 0
Tulln
Country [19] 0 0
Austria
State/province [19] 0 0
Wien
Country [20] 0 0
Bulgaria
State/province [20] 0 0
Plovdiv
Country [21] 0 0
Bulgaria
State/province [21] 0 0
Sofia
Country [22] 0 0
Canada
State/province [22] 0 0
Alberta
Country [23] 0 0
Canada
State/province [23] 0 0
Ontario
Country [24] 0 0
Canada
State/province [24] 0 0
Quebec
Country [25] 0 0
Denmark
State/province [25] 0 0
Copenhagen
Country [26] 0 0
Denmark
State/province [26] 0 0
Odense
Country [27] 0 0
Estonia
State/province [27] 0 0
Tallinn
Country [28] 0 0
Estonia
State/province [28] 0 0
Tartu
Country [29] 0 0
France
State/province [29] 0 0
Nord
Country [30] 0 0
France
State/province [30] 0 0
Nîmes
Country [31] 0 0
France
State/province [31] 0 0
Toulouse
Country [32] 0 0
Germany
State/province [32] 0 0
Baden Wuerttemberg
Country [33] 0 0
Germany
State/province [33] 0 0
Niedersachsen
Country [34] 0 0
Germany
State/province [34] 0 0
Thueringen
Country [35] 0 0
Germany
State/province [35] 0 0
Berlin
Country [36] 0 0
Hungary
State/province [36] 0 0
Budapest
Country [37] 0 0
Hungary
State/province [37] 0 0
Pécs
Country [38] 0 0
Hungary
State/province [38] 0 0
Tatabanya
Country [39] 0 0
Israel
State/province [39] 0 0
Petah Tikva
Country [40] 0 0
Israel
State/province [40] 0 0
Rehovot
Country [41] 0 0
Israel
State/province [41] 0 0
Safed
Country [42] 0 0
Israel
State/province [42] 0 0
Tel Aviv
Country [43] 0 0
Israel
State/province [43] 0 0
Tel HaShomer
Country [44] 0 0
Italy
State/province [44] 0 0
Milano
Country [45] 0 0
Italy
State/province [45] 0 0
Palermo
Country [46] 0 0
Italy
State/province [46] 0 0
Ancona
Country [47] 0 0
Italy
State/province [47] 0 0
Bologna
Country [48] 0 0
Italy
State/province [48] 0 0
Catania
Country [49] 0 0
Italy
State/province [49] 0 0
Chieti
Country [50] 0 0
Italy
State/province [50] 0 0
Pisa
Country [51] 0 0
Italy
State/province [51] 0 0
Roma
Country [52] 0 0
Italy
State/province [52] 0 0
Salerno
Country [53] 0 0
Italy
State/province [53] 0 0
Terni
Country [54] 0 0
New Zealand
State/province [54] 0 0
Christchurch
Country [55] 0 0
Poland
State/province [55] 0 0
Katowice
Country [56] 0 0
Poland
State/province [56] 0 0
Kraków
Country [57] 0 0
Poland
State/province [57] 0 0
Lublin
Country [58] 0 0
Poland
State/province [58] 0 0
Oswiecim
Country [59] 0 0
Poland
State/province [59] 0 0
Siemianowice Slaskie
Country [60] 0 0
Poland
State/province [60] 0 0
Warszawa
Country [61] 0 0
Portugal
State/province [61] 0 0
Guimaraes
Country [62] 0 0
Portugal
State/province [62] 0 0
Lisboa
Country [63] 0 0
Portugal
State/province [63] 0 0
Torres Vedras
Country [64] 0 0
Russian Federation
State/province [64] 0 0
Tatarstan
Country [65] 0 0
Russian Federation
State/province [65] 0 0
Krasnoyarsk
Country [66] 0 0
Russian Federation
State/province [66] 0 0
Moscow
Country [67] 0 0
Russian Federation
State/province [67] 0 0
Novosibirsk
Country [68] 0 0
Russian Federation
State/province [68] 0 0
Saint Petersburg
Country [69] 0 0
Russian Federation
State/province [69] 0 0
Smolensk
Country [70] 0 0
Spain
State/province [70] 0 0
Guipuzcoa
Country [71] 0 0
Spain
State/province [71] 0 0
Navarra
Country [72] 0 0
Spain
State/province [72] 0 0
Vizcaya
Country [73] 0 0
Spain
State/province [73] 0 0
Barcelona
Country [74] 0 0
Spain
State/province [74] 0 0
Cadiz
Country [75] 0 0
Spain
State/province [75] 0 0
Madrid
Country [76] 0 0
Spain
State/province [76] 0 0
Sevilla
Country [77] 0 0
Ukraine
State/province [77] 0 0
Dnipro
Country [78] 0 0
Ukraine
State/province [78] 0 0
Kharkiv
Country [79] 0 0
Ukraine
State/province [79] 0 0
Lviv
Country [80] 0 0
Ukraine
State/province [80] 0 0
Vinnytsia
Country [81] 0 0
Ukraine
State/province [81] 0 0
Zaporizhzhia
Country [82] 0 0
United Kingdom
State/province [82] 0 0
Devon
Country [83] 0 0
United Kingdom
State/province [83] 0 0
Greater London
Country [84] 0 0
United Kingdom
State/province [84] 0 0
Manchester
Country [85] 0 0
United Kingdom
State/province [85] 0 0
West Midlands
Country [86] 0 0
United Kingdom
State/province [86] 0 0
London
Country [87] 0 0
United Kingdom
State/province [87] 0 0
Salford

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Theravance Biopharma
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
A Phase 3 study to evaluate efficacy, safety, and tolerability of ampreloxetine (TD-9855) in
subjects with primary autonomic failures (MSA, PD, or PAF) and symptomatic nOH with up to 4
weeks of treatment.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03750552
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Monitor
Address 0 0
Theravance Biopharma
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03750552